{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:47:10Z","timestamp":1792813630504,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eururo.2026.02.011","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T20:27:22Z","timestamp":1773520042000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"90","author":[{"given":"Brian F.","family":"Chapin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amado J.","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Delacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Pettaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrad","family":"Adibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisly","family":"Chery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Kuban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungtaek","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elsheftawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Achim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Sei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Navin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela M.","family":"Nogueras Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.02.011_b0005","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","article-title":"Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01","volume":"25","author":"Soran","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2026.02.011_b0010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/SLA.0000000000002771","article-title":"Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial","volume":"269","author":"Fitzal","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.eururo.2026.02.011_b0015","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.02.011_b0020","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.02.011_b0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jjco\/hyz173","article-title":"A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study)","volume":"50","author":"Moritani","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.02.011_b0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.02.011_b0035","doi-asserted-by":"crossref","first-page":"202.e9","DOI":"10.1016\/j.urolonc.2015.01.022","article-title":"Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome","volume":"33","author":"Patrikidou","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.02.011_b0040","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1111\/bju.12169","article-title":"Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer","volume":"112","author":"Won","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.02.011_b0045","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.02.011_b0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.02.011_b0055","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.02.011_b0060","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.02.011_b0065","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.02.011_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2026.02.011_b0075","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial desig","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.02.011_b0080","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.eururo.2015.05.023","article-title":"A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation","volume":"69","author":"Sooriakumaran","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.02.011_b0085","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.02.011_b0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.eururo.2026.02.011_b0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.02.011_b0100","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.2967\/jnumed.123.265916","article-title":"Do bone scans overstage disease compared with PSMA PET at initial staging? An international multicenter retrospective study with masked independent readers","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.02.011_b0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1078-0432.CCR-22-2340","article-title":"Radiotherapy induces innate immune responses in patients treated for prostate cancers","volume":"29","author":"Cheema","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.02.011_b0110","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bju.15055","article-title":"The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer","volume":"125","author":"Ranasinghe","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.02.011_b0115","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.02.011_b0120","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.02.011_b0125","unstructured":"Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017;2017:PO.17.00029."},{"key":"10.1016\/j.eururo.2026.02.011_b0130","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.3390\/cancers15245843","article-title":"Evaluation of the aggressive-variant prostate cancer molecular signature in Clinical Laboratory Improvement Amendments (CLIA) environments","volume":"15","author":"Viscuse","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2026.02.011_b0135","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/cancers14133233","article-title":"Genotype-to-phenotype associations in the aggressive variant prostate cancer molecular profile (AVPC-m) components","volume":"14","author":"Soundararajan","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:26:54Z","timestamp":1785886014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826020026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0302283826020026"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.02.011","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}